Sidley Represents SanegeneBio in up to US$1.5 Billion Licensing Agreement With Genentech

Sidley represented SanegeneBio, a clinical-stage biotechnology company developing innovative RNAi therapeutics, in connection with its global licensing agreement with Genentech, a member of the Roche Group, to advance one of SanegeneBio’s RNAi programs based on its proprietary RNAi platform. Under the agreement, SanegeneBio granted Genentech exclusive worldwide rights to develop and commercialize the program, with SanegeneBio responsible for early development activities and Genentech leading subsequent clinical development and commercialization. SanegeneBio is eligible to receive a US$200 million upfront payment and will be eligible to receive development and commercialization milestone payments, totaling up to US$1.5 billion, as well as tiered royalties on future product sales.

The Sidley team was led by Asher Rubin (Technology and Life Sciences Transactions) and Feifei Bian (M&A), and included David Ryan, Cassidy Pomeroy-Carter, and Amanda Chong Artese (Technology and Life Sciences Transactions); Laura Collins, Damos Anderson, and Iva Todorova (Antitrust and Competition); and Laura DeMassa (M&A).